One of the major characteristics of vertebrate immunology is thymic involution, the shrinking (involution) of the thymus with age, resulting in changes in the architecture of the thymus and a decrease in tissue mass.  This process is genetically regulated, with the nucleic material responsible being an example of a conserved sequence — one maintained through natural selection (though the pressures shaping this are unclear as will be discussed) since it arose in a common ancestor of all species now exhibiting it, via a phenomenon known to bioinformaticists as an orthologic sequence homology. The thymus involutes in almost all vertebrates, from birds, teleosts, amphibians to reptiles, though the thymi of a few species of sharks are known not to involute.   T-cells are named for the thymus where T-lymphocytes migrate from the bone marrow to mature. Its regression has been linked to the reduction in immunosurveillance  and the rise of infectious disease and cancer incidence in the elderly (in some cases risk is inversely proportional to thymus size).  Though thymic involution has been linked to immunosenescence, it is not induced by senescence as the organ starts involuting from a young age:  in humans, as early as the first year after birth. 
Though the thymus is fully developed before birth,  newborns have an essentially empty peripheral immune compartment immediately after birth.   Hence, T lymphocytes are not present in the peripheral lymphoid tissues, where naïve, mature lymphocytes are stimulated to respond to pathogens.  In order to populate the peripheral system, the thymus increases in size and upregulates its function during the early neonatal period. 
Though some sources[which?] continue to cite puberty as the time of onset, studies have shown thymic involution to start much earlier.  The crucial distinction came from the observation that the thymus consists of two main components: the true thymic epithelial space (TES) and the perivascular space (PVS).  Thymopoiesis, or T-cell maturation, only occurs in the former. In humans, the TES starts decreasing from the first year of life at a rate of 3% until middle age (35–45 years of age), whereupon it decreases at a rate of 1% until death.  Hypothetically, the thymus should stop functioning at around 105 years of age;  but, studies with bone marrow transplant patients have shown that the thymi of the majority of patients over forty were unable to build a naïve T cell compartment. 
Effects of the involution
The ability of the immune system to mount a strong protective response depends on the receptor diversity of naive T cells (TCR). Thymic involution results in a decreased output of naïve T lymphocytes – mature T cells that are tolerant to self antigens, responsive to foreign antigens, but have not yet been stimulated by a foreign substance. In adults, naïve T-cells are hypothesized to be primarily maintained through homeostatic proliferation, or cell division of existing naïve T cells. Though homeostatic proliferation helps sustain TCR even with minimal to nearly absent thymic activity, it does not increase the receptor diversity.  For yet unknown reasons, TCR diversity drops drastically around age 65.  Loss of thymic function and TCR diversity is thought to contribute to weaker immunosurveillance of the elderly, including increasing instances of diseases such as cancers, autoimmunity, and opportunistic infections. 
Acute thymic involution and treatment implications
There is growing evidence that thymic involution is plastic and can be therapeutically halted or reversed in order to help boost the immune system. In fact, under certain circumstances, the thymus has been shown to undergo acute thymic involution (alternatively called transient involution).  For example, transient involution has been induced in humans and other animals by stresses  such as infections,   pregnancy,  and malnutrition.    The thymus has also been shown to decrease during hibernation and, in frogs, change in size depending on the season, growing smaller in the winter  Studies on acute thymic involution may help in developing treatments for patients, who for example are unable to restore immune function after chemotherapy, ionizing radiation, or infections like HIV. Research has shown the rate of thymus involution to reduce when, for men the testes, or for women the ovaries, were removed; demonstrating that sex hormones, and especially testosterone, have a marked influence on the involution process. However, the manner in which the sex hormones moderate this process is not yet fully understood. In other research the results of the Greg Fahy TRIIM trial showed clinically significant reversal of thymus involution after the administration of human growth hormone (HGH), Dehydroepiandrosterone (DHEA) and metformin. The two results could mean that HGH and mTOR inhibition in autophagy reverses thymus involution with testosterone advancing thymus involution.
Unknown selective pressures
Thymic involution remains an evolutionary mystery since it occurs in most vertebrates despite its negative effects. Since it is not induced by senescence, many scientists have hypothesized that there may have been evolutionary pressures for the organ to involute. A few hypotheses are as follows: Developing T cells that interact strongly with antigen being presented within the thymus are induced to undergo programmed cell death. The intended effect is deletion of self-reactive T cells. This works well when the antigen being presented within the thymus is truly of self origin, but antigen from pathogenic microbes that happens to infiltrate the thymus has the potential to subvert the entire process. Rather than deleting T cells that would cause autoimmunity, T cells capable of eliminating the infiltrating pathogen are deleted instead. It has been proposed that one way to minimize this problem is to produce as many long-lived T cells as possible during the time of life when the thymus is most likely to be pristine, which generally would be when organisms are very young and under the protection of a functional maternal immune system.  Thus, in mice and humans, for example, the best time to have a prodigiously functional thymus is prior to birth. In turn, it is well known from Williams'  theory of the evolution of senescence that strong selection for enhanced early function readily accommodates, through antagonistic pleiotropy, deleterious later occurring effects, thus potentially accounting for the especially early demise of the thymus. The disposable soma hypothesis and life history hypothesis say similarly that tradeoffs are involved in thymic involution. Since the immune system must compete with other bodily systems, notably reproduction, for limited physiological resources, the body must invest in the immune system differentially at different stages of life. There is high immunological investment in youth since immunological memory is low.  There are also hypotheses that suggest that thymic involution is directly adaptive. For example, some hypotheses have proposed that thymic involution may help in avoidance of autoimmunity or other dangers,  prevention of infection,  and production of an optimal repertoire of T-cells.  Zinc deficiency may also play a role. 
- Shanley D.P.; Danielle A.W.; Manley N.R.; Palmer D.B.; et al. (2009). "An evolutionary perspective on the mechanisms of immunosenescence". Trends in Immunology. 30 (7): 374–381. doi:10.1016/j.it.2009.05.001. PMID 19541538.
- Zakharova L.A. (2009). "Evolution of adaptive immunity". Izvestiia Rossiĭskoĭ Akademii Nauk. Seriia Biologicheskaia. 2 (2): 143–154. PMID 19391473.
- Linton P.J.; Dorshkind K. (2004). "Age-related changes in lymphocyte development and function". Nature Immunology. 5 (2): 133–139. doi:10.1038/ni1033. PMID 14749784. S2CID 12485241.
- Palmer S.; Albergante L.; Blackburn C.C.; Newman T.J. (2018). "Thymic involution and rising disease incidence with age". Proceedings of the National Academy of Sciences of the United States of America. 115 (8): 1883–1888. doi:10.1073/pnas.1714478115. PMC 5828591. PMID 29432166.
- Taub D.D.; Long D.L. (2005). "Insights into thymic aging and regeneration". Immunological Reviews. 205: 72–93. doi:10.1111/j.0105-2896.2005.00275.x. PMID 15882346. S2CID 24461464.
- Steinmann G.G.; Klaus B.; Muller-Hermelin H.K.; et al. (1985). "The involution of the aging human thymic epithelium is independent of puberty. A morphometric study". Scandinavian Journal of Immunology. 22 (5): 563–75. doi:10.1111/j.1365-3083.1985.tb01916.x. PMID 4081647. S2CID 40226062.
- Parham, P. 2005. The immune system: Second edition Garland Science.
- Min B.; McHugh R.; Sempowski G.D.; Mackall C.; Foucras G.; Paul W.E.; et al. (2003). "Neonates support lymphopenia-induced proliferation". Immunity. 18 (1): 131–140. doi:10.1016/S1074-7613(02)00508-3. PMID 12530982.
- Schuler T.; Hammerling G.J.; Arnold B.; et al. (2004). "Cutting edge: IL-7-dependent homeostatic proliferation of CD8+ T cells in neonatal mice allows the generation of long-lived natural memory T cells". Journal of Immunology. 172 (1): 15–19. doi:10.4049/jimmunol.172.1.15. PMID 14688303.
- George A.J.; Ritter M.A. (1996). "Thymic involution with ageing: obsolescence or good housekeeping?". Immunology Today. 17 (6): 267–272. doi:10.1016/0167-5699(96)80543-3. PMID 8962629.
- Hakim F.; Memon S.; Cepeda R.; Jones E.; Chow C.; Kasten-Sportes C.; Odom J.; Vance B.; Christensen B.; et al. (2005). "Age-dependent incidence, time course, and consequences of thymic renewal in adults". Journal of Clinical Investigation. 115 (4): 930–939. doi:10.1172/JCI22492. PMC 1064981. PMID 15776111.
- Naylor K.; Li G.; Vallejo A.N.; Lee W.W.; Koetz K.; Bryl E.; Witkowski J.; Fulbright J.; Weyand C.M.; et al. (2005). "The influence of age on T cell generation and TCR diversity". Journal of Immunology. 174 (11): 7446–7452. doi:10.4049/jimmunol.174.11.7446. PMID 15905594.
- Lynch H.E.; Goldberg G.L.; Chidgey A.; Boyd R.; Sempowski G.D.; et al. (2009). "Thymic involution and immune reconstitution". Trends in Immunology. 30 (7): 366–373. doi:10.1016/j.it.2009.04.003. PMC 2750859. PMID 19540807.
- Dominguez-Gerpe L; Rey-Mendez M (2003). "Evolution of the Thymus Size in Response to Physiological and Random Events Throughout Life". Microscopy Research and Technique. 62 (6): 464–476. doi:10.1002/jemt.10408. PMID 14635139. S2CID 45341750.
- Savino W (2006). "The thymus is a common target organ in infectious diseases". PLOS Pathogens. 2 (6): 472–483. doi:10.1371/journal.ppat.0020062. PMC 1483230. PMID 16846255.
- Savino W; Dardenne M; Velloso LA; Silva-Barbosa SD (2007). "The thymus is a common target in malnutrition and infection". British Journal of Nutrition. 98: S11–S16. doi:10.1017/s0007114507832880. PMID 17922946.
- Kendall M.D.; Clarke A.G. (2000). "The thymus in the mouse changes its activity during pregnancy: a study of the microenvironment". Journal of Anatomy. 197 (3): 393–411. doi:10.1046/j.1469-7580.2000.19730393.x. PMC 1468141. PMID 11117626.
- Cromi A.; Ghezzi F.; Raffaelli R.; Bergamini V.; Siesto G.; Bolis P.; et al. (2009). "Ultrasonographic measurement of thymus size in IUGR fetuses: a marker of the fetal immunoendocrine response to malnutrition". Ultrasound in Obstetrics & Gynecology. 33 (4): 421–426. doi:10.1002/uog.6320. PMID 19306477. S2CID 5473679.
- Howard J.K.; Lord G.M.; Matarese G.; Vendetti S.; Ghatei M.A.; Ritter M.A.; Lechler R.I.; Bloom S.R.; et al. (1999). "Leptin protects mice from starvation induced lymphoid atrophy and increases thymic cellularity in ob/ob mice" (PDF). Journal of Clinical Investigation. 104 (8): 1051–1059. doi:10.1172/JCI6762. PMC 408574. PMID 10525043.
- Wytycz, B., Mica, J., Jozkowir, A. & Bigaj J. 1996. Letters: Plasticity of thymuses of ectothermic vertebrates. Immunology Today (Comment). 442: No.9.
- "Reversing Thymic Involution – Intervene Immune". Retrieved 2020-12-31.
- Sutherland, Jayne S.; Goldberg, Gabrielle L.; Hammett, Maree V.; Uldrich, Adam P.; Berzins, Stuart P.; Heng, Tracy S.; Blazar, Bruce R.; Millar, Jeremy L.; Malin, Mark A.; Chidgey, Ann P.; Boyd, Richard L. (2005-08-15). "Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade". The Journal of Immunology. 175 (4): 2741–2753. doi:10.4049/jimmunol.175.4.2741. ISSN 0022-1767. PMID 16081852.
- Turke P (1995). "Microbial parasites versus developing T cells: an evolutionary arms race with implications for the timing of thymic involution and HIV pathenogenesis". Thymus. 24 (1): 29–40. PMID 8629277.
- Williams G. C. (1957). "Pleiotropy, natural selection, and the evolution of senescence". Evolution. 11 (4): 398–411. doi:10.2307/2406060. JSTOR 2406060.
- Aronson M (1991). "Hypothesis: involution of the thymus with aging–programmed and beneficial". Thymus. 18 (1): 7–13. PMID 1926291.
- Dowling M.R.; Hodgkin P.D. (2009). "Why does the thymus involute? A selection-based hypothesis". Trends in Immunology. 30 (7): 295–300. doi:10.1016/j.it.2009.04.006. PMID 19540805.
- Mocchegiani E, Muzzioli M, Cipriano C, Giacconi R (1998). "Zinc, T-cell pathways, aging: role of metallothioneins". Mechanisms of Ageing and Development. 106 (1–2): 183–204. doi:10.1016/S0047-6374(98)00115-8. PMID 9883983. S2CID 43299065.